TrialSignal transduction and targeted therapy2026

Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial.

Junlong Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.